Allersearch® Laboratories Lands Savvy Cleaner's CEO Angela Brown as Brand Ambassador
August 17, 2022 13:01 ET | Savvy Cleaner
CHARLOTTE, N.C., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Allersearch® Laboratories, the New Jersey-based company behind pet dander allergy relief for the last four decades, has a new message for pet...
Historic Bill Will Help Over 60 Million People with Asthma and Allergies
August 12, 2022 17:35 ET | Asthma and Allergy Foundation of America
Washington, D.C., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Today, Congress passed the Inflation Reduction Act. This bill makes significant investments to address the climate crisis and to improve access to...
Axim-Sapphire_Logo_-04 (1).png
AXIM Biotechnologies Celebrates Feature on the Vision is More Than 20/20™ Podcast
July 21, 2022 09:00 ET | AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular...
Global Allergy Diagnostics Markets, 2022-2026 & 2031 with BioMerieux, Danaher, HOB Biotech Group, HYCOR Biomedical, & Lincoln Diagnostics Dominating
June 23, 2022 04:18 ET | Research and Markets
Dublin, June 23, 2022 (GLOBE NEWSWIRE) -- The "Allergy Diagnostics Global Market Report 2022, By Allergen, By Products, By End User" report has been added to ResearchAndMarkets.com's offering.The...
intrommune_icon_500x500.png
Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy
June 22, 2022 09:31 ET | Intrommune Therapeutics
Amendment to Extend Study Duration to 48 weeks New Maintenance Period Is Designed to Evaluate Safety of INT301 After Long-term Exposure NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune...
AB Science today announced publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in the peer-reviewed Journal of Asthma and Allergy
June 07, 2022 11:45 ET | AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES PUBLICATION IN THE JOURNAL OF ASTHMA AND ALLERGY OF POSITIVE MASITINIB PHASE 3 CLINICAL TRIAL RESULTS IN PATIENTS WITH ORAL CORTICOSTEROID-DEPENDENT SEVERE ASTHMA ...
AB Science annonce aujourd'hui la publication des résultats de son étude positive du masitinib dans l'asthme sévère non contrôlé par les corticostéroïdes oraux dans la revue évaluée par des pairs Journal of Asthma and Allergy
June 07, 2022 11:45 ET | AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LA PUBLICATION DANS LA REVUE JOURNAL OF ASTHMA AND ALLERGY DES RÉSULTATS POSITIFS DE L'ETUDE DE PHASE 3 DU MASITINIB CHEZ LES PATIENTS SOUFFRANT D'ASTHME...
22157.jpg
Global Allergy Diagnostics Market Report 2022: Market to Reach US$5.7 Billion by 2026 - Increasing Prevalence and Incidence of Allergic Disorders to Drive the Demand
June 07, 2022 05:48 ET | Research and Markets
Dublin, June 07, 2022 (GLOBE NEWSWIRE) -- The "Allergy Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Allergy Diagnostics...
22157.jpg
Global Allergen Blocker Market Report to 2027 - Featuring Trutek, Prestige Brands and Ecology Works Among Others
June 07, 2022 04:53 ET | Research and Markets
Dublin, June 07, 2022 (GLOBE NEWSWIRE) -- The "Allergen Blocker Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027" report has been added to ResearchAndMarkets.com's...
Axim-Sapphire_Logo_-04 (1).png
AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures
May 24, 2022 09:00 ET | AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface...